Al-Sebeih Khalid H, Albazee Ebraheem, Alsakka Mahmoud A
Department of Otorhinolaryngology and Facial Plastic Surgery, Lothan Hospital, Salmiya, Kuwait.
Otorhinolaryngology-Head and Neck Surgery, Kuwait Institute for Medical Specializations (KIMS), Kuwait City, Kuwait.
Aesthetic Plast Surg. 2025 Feb 13. doi: 10.1007/s00266-025-04727-w.
To evaluate the safety profile of using tutoplast-processed fascia lata (TPFL) as a graft material in patients undergoing both primary and revision rhinoplasty.
PubMed, CENTRAL, Scopus, Web of Science, and EMBASE were searched. Eligible studies were evaluated for bias using the National Institutes of Health (NIH) assessment tool for cohort studies. Our safety outcomes included the incidence of graft resorption, infection, graft displacement, dorsal irregularity, overcorrected dorsal augmentation, and revision rates. Data were pooled as event rate (%) with a 95% confidence interval (CI) using STATA software.
Nine studies, comprising 827 patients, were included. Eight studies were evaluated with a low risk of bias, and one study had a moderate risk of bias. The pooled proportion analysis demonstrated a low graft resorption rate (event rate = 2.64%, 95% CI [0.69%, 5.62%]), infection rate (event rate = 0.30%, 95% CI [0.02%, 0.83%]), dorsal irregularity rate (event rate = 0.96%, 95% CI [0.09%, 2.51%]), graft displacement rate (event rate = 0.45%, 95% CI [0.07%, 1.12%]), overcorrected dorsal augmentation rate (event rate = 1.29%, 95% CI [0.39%, 2.65%]), and revision rate (event rate = 3.99%, 95% CI [1.82%, 6.90%]).
This meta-analysis of 827 patients demonstrated that TPFL has a favorable safety profile in both primary and revision rhinoplasty, with low complication and revision rates. TPFL, whether used alone or in combination with cartilage, is a viable graft option for dorsal augmentation and enhancing nasal dorsum contour.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
评估在初次隆鼻和隆鼻修复手术患者中使用经组织工程处理的阔筋膜（TPFL）作为移植材料的安全性。
检索了PubMed、CENTRAL、Scopus、Web of Science和EMBASE数据库。使用美国国立卫生研究院（NIH）队列研究评估工具对符合条件的研究进行偏倚评估。我们的安全结果包括移植吸收、感染、移植移位、鼻背不规则、鼻背过度矫正和修复率的发生率。使用STATA软件将数据合并为事件发生率（%）及95%置信区间（CI）。
纳入9项研究，共827例患者。8项研究的偏倚风险评估为低风险，1项研究为中度风险。汇总比例分析显示移植吸收率较低（事件发生率=2.64%，95%CI[0.69%，5.62%]），感染率（事件发生率=0.30%，95%CI[0.02%，0.83%]），鼻背不规则率（事件发生率=0.96%，95%CI[0.09%，2.51%]），移植移位率（事件发生率=0.45%，95%CI[0.07%，1.12%]），鼻背过度矫正率（事件发生率=1.29%，95%CI[0.39%，2.65%]）和修复率（事件发生率=3.99%，95%CI[1.82%，6.90%]）。
这项对827例患者的荟萃分析表明，TPFL在初次隆鼻和隆鼻修复手术中均具有良好的安全性，并发症和修复率较低。TPFL单独使用或与软骨联合使用，都是鼻背增高和改善鼻背轮廓的可行移植选择。
证据水平I：本刊要求作者为每篇文章指定证据水平。有关这些循证医学评级的完整描述，请参阅目录或作者在线指南www.springer.com/00266。
